Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) vs Avonex® in Patients with Relapsing-Remitting Multiple Sclerosis
The main purpose of the study is to see if the drug DAC HYP (daclizamab) is more effective than Avonex® in the treatment of MS. This study will also allow researchers to learn more about the safety of long-term treatment with DAC HYP in people with MS. The sponsor also wants to see if DAC HYP treatment affects the number and/or size of the MS lesions (abnormal spots) in the brain.ax
Who may be Eligible
The study is open to men and women ages 18 through 55, who have been diagnosed with Relapsing Remitting MS.